Skip to content

News

SGO Position Statement on Genetic Testing for Gynecologic C...

SGO Position Statement on Genetic Testing for Gynecologic Cancer

(March 20, 2014) The Society for Gynecologic Oncology has released a statement on the use of genetic testing for women with gynecologic cancer. The statement says that women diagnosed with epithelial ovarian, fallopian tube, and peritoneal cancers should receive genetic counseling and consider genetic testing, even in the absence of a family history of cancer. … Continued

Research

Avastin and Chemo for Platinum-Resistant Ovarian Cancer Inc...

Avastin and Chemo for Platinum-Resistant Ovarian Cancer Increases Progression Free Survival

(March 20, 2014) A group of French researchers conducted a randomized, phase III trial (called AURELIA) combining bevacizumab (Avastin) with chemotherapy in platinum-resistant ovarian cancer.  The results of the trial, which enrolled 361 patients, were published in the Journal of Clinical Oncology. The primary end point was progression-free survival (PFS). Secondary end points included objective … Continued

Research

New analysis links ovarian cancer to obesity

New analysis links ovarian cancer to obesity

This week, a new analysis showed that women that are overweight or obese have a moderately higher risk of developing ovarian cancer than women at normal weight. The study, released by the American Institute for Cancer Research, analyzed the data from 28 studies of over 16,000 women with ovarian cancer and showed that women who … Continued

Research

Weekly Carboplatin Plus Paclitaxel Improves Quality of Life

Weekly Carboplatin Plus Paclitaxel Improves Quality of Life

(March 14, 2014)  A large European clinical trial showed that carboplatin plus paclitaxel once a week (versus every three weeks) can be an effective front-line treatment for women with advanced ovarian cancer. The results of the study were published in the medical journal The Lancet. Carboplatin plus paclitaxel administered every 3 weeks is standard first-line … Continued

Research

OCRF Research Shows Glycans Can Identify Ovarian Cancer

OCRF Research Shows Glycans Can Identify Ovarian Cancer

OCRF-funded research at UC Davis have verified that glycans (sugars attached to proteins) can be used to identify ovarian cancer. The study was published online in the journal Cancer Epidemiology, Biomarkers & Prevention. “This is one of many papers we’ve done to see if glycans can distinguish between women who have ovarian cancer and those who … Continued

OCRA News

Ovarian Cancer Research Fund and National Sponsor QVC Expan...

Ovarian Cancer Research Fund and National Sponsor QVC Expand Woman to Woman

Program Gynecologic Cancer Patients to Receive New Support in Providence, New Orleans, Houston and The Bronx WEST CHESTER, Pa (March 10, 2014) —Ovarian Cancer Research Fund (OCRF) and QVC today announced four new Woman to Woman grant recipients: Women & Infants Hospital of Rhode Island, Providence, RI; Tulane Cancer Center, New Orleans, LA; Baylor College … Continued

OCRA News

Early oophorectomy cuts risk of death in BRCA mutation carr...

Early oophorectomy cuts risk of death in BRCA mutation carriers

New research published this week suggests that women with BRCA1 mutations should have a prophylactic oophorectomy by the age of 35 to lessen their risk of developing and dying from ovarian cancer. By contrast, the  study recommended that surgical intervention could be delayed until the 40s for BRCA2 mutation carriers. You can read the full … Continued

Research

Study Shows BRCA1 Mutation Carriers Should Remove Ovaries b...

Study Shows BRCA1 Mutation Carriers Should Remove Ovaries by Age 35

The findings of a large international study published in the Journal of Clinical Oncology suggest for the first time that women with BRCA1 mutations should have preventive ovarian surgery (prophylactic oophorectomy) by age 35. The report studied nearly 5,800 women with specific genetic mutations called BRCA1 and BRCA2. Researchers found that women with BRCA1 and … Continued

Research

High-dose Vitamin C Helps Ovarian Cancer Patients

High-dose Vitamin C Helps Ovarian Cancer Patients

(February 21, 2014) Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients. By evaluating the therapy in cells, animals, and humans, the researchers found that a combination of … Continued

Research

High-dose Vitamin C may boost chemotherapy effectiveness

High-dose Vitamin C may boost chemotherapy effectiveness

High-doses of vitamin C delivered in conjunction with IV chemotherapy may boost chemotherapy’s effectiveness and reduce side-effects in ovarian cancer treatment, according to a new study published this week. Researchers from the University of Kansas Medical Center found that patients who received vitamin C in conjunction with the conventional chemotherapy drugs paclitaxel or carboplatin reported … Continued

Research

Regular Aspirin Use May Reduce Ovarian Cancer Risk

Regular Aspirin Use May Reduce Ovarian Cancer Risk

(February 10, 2014) Women who take aspirin daily may reduce their risk of ovarian cancer by 20 percent, according to a study by scientists at the National Cancer Institute (NCI).  However, further research is needed before clinical recommendations can be made. The study, which was conducted as part of the OCRF-funded Ovarian Cancer Association Consortium, … Continued

Research

Press Release: Ovarian Cancer Advocates Applaud Findings on...

Press Release: Ovarian Cancer Advocates Applaud Findings on Aspirin and Risk Reduction

FOR IMMEDIATE RELEASE: February 7, 2014 Further Study Needed Before Clinical Recommendations Change Washington, DC—A study published yesterday by the National Institutes of Health found that women who took aspirin on a daily basis had a 20 percent reduction in risk of ovarian cancer. The Ovarian Cancer National Alliance released the following statement in response … Continued

OCRA News

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.